Partial Agonists, Efficacy, and Intrinsic Activity

A partial agonist is a ligand that activates a receptor but, even at full occupancy, produces a response smaller than the system maximum. Partial agonists sit between full agonists and antagonists on the efficacy continuum, and historically were described by their intrinsic activity — the ratio of their maximal effect to that of a full agonist. A distinctive feature is that, in the presence of a full agonist, a partial agonist can reduce the overall response, behaving as a functional antagonist.

Definition

A partial agonist is a ligand whose maximal achievable response is below the system maximum even when receptor occupancy is complete, reflecting an intrinsic efficacy that is positive but lower than that of a full agonist; intrinsic activity historically expressed this as the ratio of the ligand's maximal effect to that of a reference full agonist.

Scope

This topic covers the definition of a partial agonist, the classical concept of intrinsic activity, the modern parameter of efficacy, and the dual agonist-antagonist behaviour of partial agonists. It is a methodological reference within pharmacodynamics and does not address drug selection or dosing.

Core questions

• What distinguishes a partial agonist from a full agonist and from an antagonist?
• How do the classical 'intrinsic activity' and modern 'efficacy' concepts differ?
• Why can a partial agonist reduce the response in the presence of a full agonist?
• How does receptor reserve influence whether a ligand appears full or partial?

Key concepts

• Intrinsic activity
• Intrinsic efficacy
• Submaximal Emax / ceiling effect
• Partial agonist as functional antagonist
• Efficacy continuum
• System dependence (reserve)

Key theories

Efficacy and intrinsic activity

Ariens' intrinsic activity (a proportionality term scaling maximal effect) and Stephenson's efficacy (a property of the drug-receptor complex) recast partial agonism as a graded property; modern usage treats efficacy as the parameter that places ligands on a continuum from full agonist to inverse agonist.

Operational (Black-Leff) model

Represents a partial agonist as having an intermediate transducer ratio, so its concentration-response curve saturates below the tissue maximum even at full occupancy.

Mechanisms

A partial agonist binds and activates the receptor but stabilises the active state less effectively than a full agonist, so the fraction of receptors in the active conformation, and hence the maximal response, is lower. Because the response reaches a ceiling below the system maximum even at saturating concentrations, a partial agonist cannot fully substitute for a full agonist. When a full agonist is also present and receptors are limiting, the partial agonist competes for occupancy and replaces high-efficacy binding with lower-efficacy binding, lowering the net response — the basis of its functional (apparent) antagonism. Whether a given ligand presents as full or partial also depends on the receptor reserve of the tissue: in a highly amplified system a ligand of moderate efficacy may appear nearly full, while in a system with little reserve the same ligand appears clearly partial.

Clinical relevance

Partial agonism underlies the behaviour of several important drug classes and explains characteristic features such as a ceiling on effect and the ability to either stimulate or dampen a response depending on the prevailing level of endogenous agonist. This entry is reference material on how partial agonist action is defined and quantified; it is not a basis for individual treatment or dosing decisions.

Evidence & guidelines

The terms partial agonist, efficacy, and intrinsic activity used here follow the IUPHAR recommendations on terms and symbols in quantitative pharmacology.

History

The idea that agonists differ in the maximum they can produce emerged from Ariens' (1954) concept of intrinsic activity and Stephenson's (1956) concept of efficacy, which separated the strength of receptor activation from binding affinity. The operational model of Black and Leff (1983) later gave partial agonism a quantitative form as an intermediate efficacy parameter, and subsequent receptor-state models linked it to the proportion of receptors stabilised in the active conformation.

Key figures

• E. J. Ariens
• R. P. Stephenson
• James W. Black
• Paul Leff
• David Colquhoun

Seminal works

• black-leff-1983
• colquhoun-1998
• neubig-2003

Frequently asked questions

Why does a partial agonist have a 'ceiling' on its effect?

Because its intrinsic efficacy is lower than a full agonist's, it cannot drive the receptor system to its maximum, so the response levels off below the system maximum even when every receptor is occupied.

How can the same drug act as both an agonist and an antagonist?

On its own a partial agonist produces a submaximal response. When a full agonist is also present, the partial agonist competes for receptors and lowers the overall response, so it behaves as a functional antagonist in that setting.